These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25967573)

  • 21. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke.
    Savitz SI; Schlaug G; Caplan L; Selim M
    Stroke; 2005 Jul; 36(7):1447-51. PubMed ID: 15947268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model.
    Tomkins AJ; Hood RJ; Levi CR; Spratt NJ
    Sci Rep; 2015 Nov; 5():16026. PubMed ID: 26522691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occult anterograde flow is an under-recognized but crucial predictor of early recanalization with intravenous tissue-type plasminogen activator.
    Ahn SH; d'Esterre CD; Qazi EM; Najm M; Rubiera M; Fainardi E; Hill MD; Goyal M; Demchuk AM; Lee TY; Menon BK
    Stroke; 2015 Apr; 46(4):968-75. PubMed ID: 25700286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Early Arterial Recanalization and Tissue Fate in the Selection of Patients With the Greatest Potential to Benefit From Intravenous Tissue-Type Plasminogen Activator.
    Leiva-Salinas C; Patrie JT; Xin W; Michel P; Jovin T; Wintermark M
    Stroke; 2016 Feb; 47(2):397-403. PubMed ID: 26696647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-Arterial Therapy and Post-Treatment Infarct Volumes: Insights From the ESCAPE Randomized Controlled Trial.
    Al-Ajlan FS; Goyal M; Demchuk AM; Minhas P; Sabiq F; Assis Z; Willinsky R; Montanera WJ; Rempel JL; Shuaib A; Thornton J; Williams D; Roy D; Poppe AY; Jovin TG; Sapkota BL; Baxter BW; Krings T; Silver FL; Frei DF; Fanale C; Tampieri D; Teitelbaum J; Lum C; Dowlatshahi D; Shankar JJ; Barber PA; Hill MD; Menon BK;
    Stroke; 2016 Mar; 47(3):777-81. PubMed ID: 26892284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circadian rhythms in the efficacy of intravenous alteplase in patients with acute ischemic stroke and middle cerebral artery occlusion.
    Vilas D; Gomis M; Blanco M; Cortés J; Millán M; Pérez de la Ossa N; Dorado L; López-Cancio E; Suñol A; Dávalos A
    Chronobiol Int; 2012 Dec; 29(10):1383-9. PubMed ID: 23130962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.
    Uchino K; Alexandrov AV; Garami Z; El-Mitwalli A; Morgenstern LB; Grotta JC
    Cerebrovasc Dis; 2005; 19(4):260-6. PubMed ID: 15731557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-Vessel Occlusion Stroke: Effect of Recanalization on Outcome Depends on the National Institutes of Health Stroke Scale Score.
    Skagen K; Skjelland M; Russell D; Jacobsen EA
    J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1532-9. PubMed ID: 25922156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol.
    Ribo M; Molina CA; Rovira A; Quintana M; Delgado P; Montaner J; Grivé E; Arenillas JF; Alvarez-Sabín J
    Stroke; 2005 Mar; 36(3):602-6. PubMed ID: 15692107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barriers to the use of intravenous tissue plasminogen activator for in-hospital strokes.
    Bunch ME; Nunziato EC; Labovitz DL
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):808-11. PubMed ID: 21640608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis.
    Kharitonova TV; Melo TP; Andersen G; Egido JA; Castillo J; Wahlgren N;
    Stroke; 2013 Sep; 44(9):2513-8. PubMed ID: 23881960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative Imaging of Cerebral Thromboemboli In Vivo: The Effects of Tissue-Type Plasminogen Activator.
    Kim DE; Kim JY; Schellingerhout D; Ryu JH; Lee SK; Jeon S; Lee JS; Kim J; Jang HJ; Park JE; Kim EJ; Kwon IC; Ahn CH; Nahrendorf M; Kim K
    Stroke; 2017 May; 48(5):1376-1385. PubMed ID: 28432262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).
    De Silva DA; Brekenfeld C; Ebinger M; Christensen S; Barber PA; Butcher KS; Levi CR; Parsons MW; Bladin CF; Donnan GA; Davis SM;
    Stroke; 2010 Feb; 41(2):295-9. PubMed ID: 20056931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO).
    Saqqur M; Tsivgoulis G; Molina CA; Demchuk AM; Garami Z; Barreto A; Spengos K; Forteza A; Mikulik R; Sharma VK; Brunser A; Martinez P; Montaner J; Kohrmann M; Schellinger PD; Alexandrov AV;
    Int J Stroke; 2008 Feb; 3(1):66-72. PubMed ID: 18705918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.